Prostatype Genomics AB (publ)

Stockholm Stock Exchange PROGEN.ST

Prostatype Genomics AB (publ) EBITDA for the year ending December 31, 2023: USD -3.75 M

Prostatype Genomics AB (publ) EBITDA is USD -3.75 M for the year ending December 31, 2023, a -46.70% change year over year. EBITDA means earnings before interest, taxes, depreciation, and amortization, which measures a company's operating performance by excluding non-operating expenses.
  • Prostatype Genomics AB (publ) EBITDA for the year ending December 31, 2022 was USD -2.56 M, a -50.29% change year over year.
  • Prostatype Genomics AB (publ) EBITDA for the year ending December 31, 2021 was USD -1.70 M, a 10.92% change year over year.
  • Prostatype Genomics AB (publ) EBITDA for the year ending December 31, 2020 was USD -1.91 M.
Key data
Date EBITDA Net Income EPS (Diluted) Shares (Diluted, Weighted)
Market news
Stockholm Stock Exchange: PROGEN.ST

Prostatype Genomics AB (publ)

CEO Mr. Fredrik Rickman
IPO Date Nov. 3, 2020
Location Sweden
Headquarters Industrivägen 19
Employees 6
Sector Health Care
Industries
Biotechnology Clinical Trials Pharmaceuticals
Description

Prostatype Genomics AB manufactures, markets, and sells the prognostic gene tests. It offers Prostatype Test System that combines gene expression information with used clinical parameters, such as PSA, Gleason Score, and Tumor Stage, as well as calculates the P-score. The test is based on database containing prostate cancer patients and provides decision support for patients and doctors when making a treatment decision. The company was founded in 2007 and is based in Solna, Sweden.

Similar companies

SPRINT.ST

Sprint Bioscience AB (publ)

USD 0.14

1.34%

StockViz Staff

January 15, 2025

Any question? Send us an email